Only three driver gene mutations are required for the development of lung and colorectal cancers - PubMed (original) (raw)
Only three driver gene mutations are required for the development of lung and colorectal cancers
Cristian Tomasetti et al. Proc Natl Acad Sci U S A. 2015.
Abstract
Cancer arises through the sequential accumulation of mutations in oncogenes and tumor suppressor genes. However, how many such mutations are required for a normal human cell to progress to an advanced cancer? The best estimates for this number have been provided by mathematical models based on the relation between age and incidence. For example, the classic studies of Nordling [Nordling CO (1953) Br J Cancer 7(1):68-72] and Armitage and Doll [Armitage P, Doll R (1954) Br J Cancer 8(1):1-12] suggest that six or seven sequential mutations are required. Here, we describe a different approach to derive this estimate that combines conventional epidemiologic studies with genome-wide sequencing data: incidence data for different groups of patients with the same cancer type were compared with respect to their somatic mutation rates. In two well-documented cancer types (lung and colon adenocarcinomas), we find that only three sequential mutations are required to develop cancer. This conclusion deepens our understanding of the process of carcinogenesis and has important implications for the design of future cancer genome-sequencing efforts.
Keywords: cancer; cancer evolution; cancer incidence; driver mutations; somatic mutation rate.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Fig. 1.
Distributions of the total number of somatic mutations and of the somatic mutation rates (somatic mutations per year) in smokers (blue) and never-smokers (red) in LUAD. The rightmost parts of the red distributions have been excluded to facilitate comparison. Distributions of the number of somatic mutations (A) and of the somatic mutation rates (B).
Fig. 2.
Distributions of the total number of somatic mutations (A and C) and of the somatic mutation rates (somatic mutations per year) (B and D) in MMR-proficient (MSS or _MLH1_-normal) and MMR-deficient (MSI or _MLH1_-silent) CRCs. The rightmost parts of each red distribution have been excluded to facilitate comparison.
Fig. 3.
Relation between the number of rate-limiting driver mutations and the increase in LUAD incidence observed in smokers. The observed average increase in LUAD incidence associated with smoking is 16.2-fold (red line); the pink area is its 99% CI (10.25–25.6) (23). The expected increase in LUAD incidence associated with the indicated number of rate-limiting mutations is represented by the blue marks, with the corresponding 95% CI indicated by blue vertical segments.
Fig. 4.
Relation between the number of rate-limiting driver mutations and the increase in CRC incidence observed in patients with MMR deficiency. The observed average increase in incidence associated with MMR deficiency is 114.2-fold (red line); the pink area is its 95% CI (60.7–217) (14). The expected increase in CRC incidence associated with the indicated number of rate-limiting mutations is represented by the blue marks, with the corresponding 95% CI indicated by blue vertical segments.
Similar articles
- Population risk and physiological rate parameters for colon cancer. The union of an explicit model for carcinogenesis with the public health records of the United States.
Herrero-Jimenez P, Tomita-Mitchell A, Furth EE, Morgenthaler S, Thilly WG. Herrero-Jimenez P, et al. Mutat Res. 2000 Jan 17;447(1):73-116. doi: 10.1016/s0027-5107(99)00201-8. Mutat Res. 2000. PMID: 10686307 - Toward an evolutionary model of cancer: Considering the mechanisms that govern the fate of somatic mutations.
Rozhok AI, DeGregori J. Rozhok AI, et al. Proc Natl Acad Sci U S A. 2015 Jul 21;112(29):8914-21. doi: 10.1073/pnas.1501713112. Proc Natl Acad Sci U S A. 2015. PMID: 26195756 Free PMC article. - Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
Li H, Pan Y, Li Y, Li C, Wang R, Hu H, Zhang Y, Ye T, Wang L, Shen L, Sun Y, Chen H. Li H, et al. Lung Cancer. 2013 Jan;79(1):8-13. doi: 10.1016/j.lungcan.2012.09.018. Epub 2012 Oct 23. Lung Cancer. 2013. PMID: 23098378 - Cigarette smoking and K-ras mutations in pancreas, lung and colorectal adenocarcinomas: etiopathogenic similarities, differences and paradoxes.
Porta M, Crous-Bou M, Wark PA, Vineis P, Real FX, Malats N, Kampman E. Porta M, et al. Mutat Res. 2009 Sep-Dec;682(2-3):83-93. doi: 10.1016/j.mrrev.2009.07.003. Epub 2009 Aug 3. Mutat Res. 2009. PMID: 19651236 Review. - Molecular biology of colorectal cancer.
Gryfe R, Swallow C, Bapat B, Redston M, Gallinger S, Couture J. Gryfe R, et al. Curr Probl Cancer. 1997 Sep-Oct;21(5):233-300. doi: 10.1016/s0147-0272(97)80003-7. Curr Probl Cancer. 1997. PMID: 9438104 Review.
Cited by
- Hydrogel-based platforms for site-specific doxorubicin release in cancer therapy.
Zang C, Tian Y, Tang Y, Tang M, Yang D, Chen F, Ghaffarlou M, Tu Y, Ashrafizadeh M, Li Y. Zang C, et al. J Transl Med. 2024 Sep 30;22(1):879. doi: 10.1186/s12967-024-05490-3. J Transl Med. 2024. PMID: 39350207 Free PMC article. Review. - CDMPred: a tool for predicting cancer driver missense mutations with high-quality passenger mutations.
Wang L, Sun H, Yue Z, Xia J, Li X. Wang L, et al. PeerJ. 2024 Sep 6;12:e17991. doi: 10.7717/peerj.17991. eCollection 2024. PeerJ. 2024. PMID: 39253604 Free PMC article. - Association of KRAS Mutation and Gene Pathways in Colorectal Carcinoma: A Transcriptome- and Methylome-Wide Study and Potential Implications for Therapy.
Jasmine F, Almazan A, Khamkevych Y, Bissonnette M, Ahsan H, Kibriya MG. Jasmine F, et al. Int J Mol Sci. 2024 Jul 25;25(15):8094. doi: 10.3390/ijms25158094. Int J Mol Sci. 2024. PMID: 39125664 Free PMC article. - Single cell spatial biology over developmental time can decipher pediatric brain pathologies.
Nussinov R, Yavuz BR, Jang H. Nussinov R, et al. Neurobiol Dis. 2024 Sep;199:106597. doi: 10.1016/j.nbd.2024.106597. Epub 2024 Jul 9. Neurobiol Dis. 2024. PMID: 38992777 Review. - Recharacterization of RSL3 reveals that the selenoproteome is a druggable target in colorectal cancer.
DeAngelo SL, Zhao L, Dziechciarz S, Shin M, Solanki S, Balia A, El-Derany MO, Castillo C, Qin Y, Das NK, Bell HN, Paulo JA, Zhang Y, Rossiter NJ, McCulla EC, He J, Talukder I, Ng BW, Schafer ZT, Neamati N, Mancias JD, Koutmos M, Shah YM. DeAngelo SL, et al. bioRxiv [Preprint]. 2024 Aug 27:2024.03.29.587381. doi: 10.1101/2024.03.29.587381. bioRxiv. 2024. PMID: 38617233 Free PMC article. Preprint.
References
- Knudson AG. Two genetic hits (more or less) to cancer. Nat Rev Cancer. 2001;1(2):157–162. - PubMed
- Little MP. Are two mutations sufficient to cause cancer? Some generalizations of the two-mutation model of carcinogenesis of Moolgavkar, Venzon, and Knudson, and of the multistage model of Armitage and Doll. Biometrics. 1995;51(4):1278–1291. - PubMed
Publication types
MeSH terms
Grants and funding
- R37 CA043460/CA/NCI NIH HHS/United States
- HHMI/Howard Hughes Medical Institute/United States
- R37CA43460/CA/NCI NIH HHS/United States
- P30CA006973/CA/NCI NIH HHS/United States
- P30 CA006973/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical